The effects of Bifidobacterium animalis subsp. lactis BLa80 on glycemic control and gut microbiota in patients with T2DM: a randomized, double-blind, placebo-controlled trial.

To evaluate the effect of Bifidobacterium subsp. lactis BLa80 on glycemic control and gut microbiota composition in patients with type 2 diabetes mellitus (T2DM), a randomized, placebo-controlled clinical trial was conducted in 80 patients. Participants were randomly assigned to receive either BLa80 supplementation or placebo (n = 40 per group) in addition to standard metformin therapy for 12 weeks. Fasting blood and stool samples were collected at baseline and at the end of the intervention. The results showed that BLa80 supplementation significantly reduced fasting blood glucose and high-density lipoprotein cholesterol (HDL-C) levels, while low-density lipoprotein cholesterol (LDL-C) levels were increased. Furthermore, BLa80 modulated the diversity and composition of the gut microbiota after 12 weeks of intervention. In conclusion, BLa80 supplementation may improve glycemic control and modulate the gut microbiota in patients with T2DM, suggesting its potential as an adjunctive therapy in diabetes management.